Indication intelligence, analysis and sector perception

BioTime (NYSEMKT: BTX) to sell $20.7 M in registered direct offering

September 26, 2015 11:19am

Shares to be sold to TASE Index Funds in Israel; BTX closed DOWN -$0.13 to $3.50 on 354 K volume <3 month average = 276.1 K shares>. Friday’s aftermarket release had BTX down another -$0.06 <-1.71%>, expect more depreciation - SELL

BioTime, Inc. (NYSE MKT and TASE: BTX) today announced that it has agreed to sell up to $20.7 million of its common shares in a registered direct offering to select investment funds in Israel that hold shares of companies that are included within certain stock indexes of the Tel Aviv Stock Exchange (the TASE).

The price per share will be determined with reference to the closing price of BioTime (BTIM-RETIRED) common shares on the TASE on the trading day immediately preceding the first day on which BioTime common shares enter the TASE stock indexes.

The Bottom Line: The sale of the common shares is expected to close on or about October 1, 2015. The amount of aggregate proceeds from the sale and the total number of shares sold will depend upon the market price of BioTime common shares and the number of BioTime common shares the investment funds need to purchase from BioTime to put their portfolios in balance with the TASE stock indexes that they track.

Prognosis: Let BTX settle after the offering concludes, it will be time to re-visit a BUY

BioTime will pay Union Underwriting & Finances Ltd an investment banking fee in the amount of 1% of the aggregate purchase price of the common shares sold.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

3 hours 22 min ago
RegMed Investors (RMi) Closing Bell: a tough week; tied to cross-currents of geopolitical conflicts and recurring inflation

15 hours 5 min ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.